Skip to main content
. 2020 Sep 14;111(11):4195–4204. doi: 10.1111/cas.14632

Figure 1.

Figure 1

Survival of mucoepidermoid carcinoma (MEC) patients according to CRTC1/3‐MAML2 fusions. A, C, E, Overall survival in total (A, N = 153), early‐stage (C, N = 69), and advanced‐stage (E, N = 84) MEC cohorts. B, D, F, Disease‐free survival in total (B), early‐stage (D), and advanced‐stage (F) MEC cohorts. In the early‐stage cohort (C), prognostic analysis for overall survival was not carried out because only one patient died during the follow‐up period